Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics 
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Glutamate (EAAT) Transporters
More Information »Glutamate transporters, also known as excitatory amino acid transporters (EAATs), are sodium- and potassium-dependent members of the solute carrier family 6 (SLC1), widely distributed throughout the brain. There are five EAAT subtypes, each with a specific distribution.
Glutamate Transporter Products
Inhibitors |
|
Cat.No. |
Product Name / Activity |
| 0271 | cis-ACBD |
| Potent, selective L-glutamate uptake inhibitor | |
| 0332 | L-CCG-lll |
| Potent, competitive glutamate uptake inhibitor | |
| 0846 | Chicago Sky Blue 6B |
| Potent inhibitor of L-glutamate uptake into synaptic vesicles; also inhibits MIF | |
| 3697 | 7-Chlorokynurenic acid sodium salt |
| Potent competitive inhibitor of L-glutamate uptake. Sodium salt of 7-Chlorokynurenic acid (Cat. No. 0237) | |
| 0237 | 7-Chlorokynurenic acid |
| Potent competitive inhibitor of L-glutamate uptake | |
| 0111 | Dihydrokainic acid |
| EAAT2 (GLT-1)-selective non-transportable inhibitor of L-glutamate and L-aspartate uptake | |
| 0845 | Evans Blue tetrasodium salt |
| Potent inhibitor of L-glutamate uptake into synaptic vesicles | |
| 2217 | (±)-HIP-A |
| Potent, non-competitive EAAT inhibitor | |
| 2218 | (±)-HIP-B |
| Potent, non-competitive EAAT inhibitor | |
| 0183 | L-(-)-threo-3-Hydroxyaspartic acid |
| Transportable EAAT1-4 inhibitor/non-transportable EAAT5 inhibitor | |
| 0811 | (±)-threo-3-Methylglutamic acid |
| EAAT2 and EAAT4 blocker | |
| 0973 | MPDC |
| Potent inhibitor of L-glutamate uptake. Less activity as a substrate compared to its parent compound, L-trans-2,4-PDC (Cat. No. 0298) | |
| 0298 | L-trans-2,4-PDC |
| Transportable EAAT1-4 inhibitor/non-transportable EAAT5 inhibitor | |
| 0903 | SYM 2081 |
| Inhibits EAAT2. Also kainate receptor agonist | |
| 1223 | DL-TBOA |
| Selective non-transportable inhibitor of EAATs | |
| 2532 | TFB-TBOA |
| High affinity EAAT1 and EAAT2 blocker | |
| 3490 | UCPH 101 |
| Selective non-substrate EAAT1 inhibitor | |
| 2652 | WAY 213613 |
| Potent, non-substrate EAAT2 inhibitor | |
Ligand Sets |
|
Cat.No. |
Product Name / Activity |
| 1830 | Excitatory Amino Acid Transporter Inhibitor Tocriset™ |
| Selection of 5 EAAT inhibitors (Cat. Nos. 0183, 0298, 1223, 0111 and 0903) | |
Other |
|
Cat.No. |
Product Name / Activity |
| 3732 | Ceftriaxone disodium salt |
| Neuroprotective; increases EAAT2 expression and activity | |
| 2277 | MNI-caged-D-aspartate |
| Caged D-aspartate; EAAT substrate | |
Related Categories
Quick Order
Find multiple products by catalog number
Calcium Imbalance and Neuroprotective Targets
Written by E. Besancon et al
'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
Tocris Events
Meet your representative
The Role of Cytokines and Signaling in Inflammation
October 15, 2013
Bonn, Germany